Finally, we show that GZ17-6.02 downregulates several GSC super-enhancer genes, which are key to EGFR signaling and GSC proliferation [8], and demonstrate that GZ17-6.02 suppresses tumor growth in a subcutaneous tumor model. This evidence concerns the gene EGFR and neoplasm.